BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria - PressReach

Open the article to view the coverage from pressreach.com

BioCity's SC0062 gains BTD from NMPA

The CDE of China's NMPA has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second BTD.

BioCity’s SC0062 wins breakthrough status for kidney disease treatment

SHANGHAI, June 26, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to its highly selective endothelin receptor type A (ETA) antagonist SC0062 for the treatment of diabetic kidney disease (DKD) with albuminuria. This marks the second BTD for SC0062, following its initial designa…